Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review

Lung cancer remains one of the most frequent and most deadly tumor entities, with 1.6 million tumor-related deaths annually worldwide. Lung cancer in patients who have never smoked has attracted growing interest because of treatable oncogenic alterations and the opportunity for individualized treatment. The identification of activating mutations in EGFR, mostly seen in exon 19 (deletion) or in exon 21 (L858R point mutation), together with an increased sensitivity to EGFR tyrosine kinase inhibitors, has been the first and most important step toward molecular-guided precision therapy of lung cancer.

Source: Lung Cancer - February 27, 2020 Category: Cancer & Oncology Authors: Maddalena Mancin, Alessia Pastore, Davide Seminati, Diego Cortinovis, Paolo Bidoli, Andrea Alberti, Luca Sala Source Type: research